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From the editor 
Introduction 
As part of the American Recovery and 
Reinvestment Act (ARRA), Congress mandated 
that the Institute of Medicine (IOM) establish a 
list of Comparative Effectiveness Research (CER) 
priorities by June 30, 2009. ARRA authorized a 
$1.1 billion down payment to support national 
CER efforts. Of the total funds, $400 million is to 
be released by the Secretary of Health and Human 
Services, and is likely to be targeted towards topics 
consistent with the IOM list. Another $400 million 
is to be released by the National Institutes of 
Health (NIH), and the remaining $300 million is 
to be dispersed by Agency for Healthcare Research 
and Quality (AHRQ). At the time of this writing, 
there were two Congressional proposals to sustain 
national CER efforts. In a recent interview about 
health reform, President Obama supported CER in 
saying “There’s always going to be an asymmetry 
of information between patient and provider. 
Part of what I think government can do is to be 
an honest broker in assessing and evaluating 
treatment options.”1
What is Comparative Effectiveness Research? 
The IOM Committee defined CER as “the 
generation and synthesis of evidence that compares 
the benefits and harms of alternative methods 
to prevent, diagnose, treat and monitor a clinical 
condition, or to improve the delivery of care. The 
purpose of CER is to assist consumers, clinicians, 
purchasers, and policy makers to make informed 
decisions that will improve health care at both the 
individual and population levels.” 2,3   
The report states six characteristics of CER:
1. CER has the objective of directly informing 
a specific clinical decision from the patient 
perspective or a health policy decision from the 
population perspective.
2. CER compares at least two alternative 
interventions, each with the potential to be  
“best practice.”
3. CER describes results at the population and 
subgroup levels.
4. CER measures outcomes - both benefits and 
harms - that are important to patients.
5. CER employs methods and data sources 
appropriate for the decision of interest.
6.  CER is conducted in settings that are similar to  
those in which the intervention will be used in practice.
The premise of CER is simple: we should invest 
in the medical treatments that are proven to be 
effective in defined patient populations in real-
world practice settings. CER can be conducted 
using a variety of approaches, including 
randomized trials, prospective observational 
studies, database analyses, and systematic reviews 
- all methods of population health research. CER 
is conducted in settings that are similar to those in 
which the intervention will be used in practice.
The IOM Committee created a list of 100 
recommended priorities, through a structured 
review of potential topics identified through a 
national survey.  The full list is available at:  
www.iom.edu/cerpriorities.  Priorities in the top 
quartile include comparing the effectiveness of 
treatment strategies for: atrial fibrillation; hearing 
loss; dementia; prostate cancer; dental caries; 
ADHD and obesity in children; prevention of 
falls in older adults; chronic care management 
programs; biologics for inflammatory diseases; 
screening, prophylaxis and treatment programs 
for methicillin resistant staphylococcus aureus 
(MRSA) and healthcare acquired infection; and 
genetic and biomarker testing for certain cancers. A 
broad array of interventions was recommended to 
evaluate these priorities, including systems of care; 
pharmacological treatment; behavioral treatment; 
prevention; procedures; testing, monitoring, and 
evaluation; devices; standard of care; alternative 
treatment; provider-patient relationships; and 
treatment pathways.
CER provides clinicians and health plans with 
the ability to compare treatments to each other 
(or to usual care) rather than to placebo, and to 
understand the effectiveness of treatments in defined 
populations. Though manufacturers will continue 
placebo-controlled trials in order to meet FDA 
requirements, CER will provide real-world evidence 
on competing treatments via head to head trials, 
observational studies, and database analyses (for 
example, patient registries or claims datasets). CER 
will also elucidate the effectiveness of treatments in 
groups typically underrepresented in clinical trials, 
such as children, the elderly, and minority groups. 
Role of Economic Analysis in CER 
Applied health economic analysis is an important 
component of CER because it reveals which 
treatments yield maximal value. Applied health 
economics involves weighing effectiveness and costs 
of competing treatment interventions, typically via 
formal cost effectiveness analyses. First published 
nearly two decades ago, best practices for cost 
effectiveness analysis have stood the test of time - 
with a significant increase in published studies in 
recent years.4    Opponents to including cost in CER 
fear that it may impede patients’ access to expensive 
care; however, cost effectiveness analysis often 
recommends the use of more expensive treatments if 
they produce better outcomes. Thus, cost effectiveness 
does not necessarily translate to cost savings, but 
may instead mean better results for the dollars spent. 
This type of analysis becomes increasingly important 
when competing treatments are equally effective, or 
have marginal differences in effectiveness.5
Jefferson School of Population Health: Committed 
to Developing the CER Workforce
The IOM Committee report noted that the career 
pathways for CER are not clear, and there is a lack 
of federally funded graduate and post-graduate 
training programs aimed at grooming investigators in 
population health research. The committee predicted 
a “substantial need” for experts in the disciplines of 
CER, including outcomes research, observational data 
analysis, cost effectiveness, statistical modeling, and 
epidemiology.2 
The Jefferson School of Population Health anticipates 
this growing national need for CER researchers. 
Through our existing two-year postdoctoral 
fellowships in applied health economics and 
outcomes research, JSPH has trained more than 30 
professionals in the methods of CER during the past 
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15 years.  This past year, we doubled the number 
of available fellowship slots from 2 to 4. Moving 
ahead, we are committed to further building the 
CER workforce with graduate-level degrees centered 
on CER methods, particularly a Master of Science 
degree in Applied Health Economics (presently 
in development). This degree will focus on the 
methods of cost effectiveness analysis, observational 
studies, health utility and quality of life outcomes 
research, and economic modeling. It will be the 
first in the US to emphasize important population 
health interventions such as screening programs, 
vaccinations, occupational and physical therapy, 
surgical techniques, dietary modification and exercise 
regimens.  We believe that the CER workforce of the 
future will be called upon to evaluate this broad array 
of population health interventions in addition to the 
traditional evaluation of new drugs and devices.
As we move forward in shaping this degree,  
we welcome your views and opinions. With  
your input, we hope to build a strong and 
sustainable program which develops national 
leaders in CER.   
Laura Pizzi, PharmD, MPH 
Associate Professor 
Director of Health Economics and  
Outcomes Research  
Jefferson School of Population Health 
The author may be reached at:   
laura.pizzi@jefferson.edu.
RefeRences
1. Leonhardt D. After the great recession: An interview with President Obama. New York Times Magazine, May 3, 2009.
2. Institute of Medicine. Initial national priorities for comparative effectiveness research.  Washington, DC: National Academies Press; 2009. 
3. Sox HC and Greenfield S. Comparative Effectiveness Research: A Report From the Institute of Medicine. Annals of Intern Med 2009; 151(3):203-205. 
http://www.annals.org/cgi/content/short/151/3/203.   Accessed  August 20, 2009.
4. Pizzi LT and Singh VM. Pharmacoeconomics is coming of age (Macroscopy). Clin Pharmacol &Ther.  2008; 84(2):189-190.
5. Hoffman A and Pearson SD. Marginal medicine: Targeting comparative effectiveness research to reduce waste. Health Affairs. 2009; 28(4): w710-w718.
